Elad Sharon, Clinical and Translational Director of Immunotherapy Toxicity Program at Dana-Farber Cancer Institute, shared a post on X:
“Getting started early here in ESMO25 in Berlin with the international neoadjuvant melanoma consortium! Michael Tetzloff of UCSF with definitions of pathological response in this important area!”
More posts featuring ESMO25.
